$CAUD
Collective Audience, Inc. Stock $caud

$caud Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023067177 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$30.00K
YoY Change
Gross Profit		-$30.00K
YoY Change
Gross Profit Margin
Selling, General & Admin	$249.0K	$186.9K	$197.5K
YoY Change	46.66%	-5.34%	20927.8%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$499.5K	$528.0K	$504.6K
YoY Change	-31.36%	4.65%	1530.97%
Operating Profit	-$499.5K	-$528.0K	-$504.6K
YoY Change	-31.36%	4.65%	1530.97%
Interest Expense	$130.5K	$177.2K	$117.9K
YoY Change	-60.39%	50.33%
% of Operating Profit
Other Income/Expense, Net	-$25.04K	$16.20K
YoY Change
Pretax Income	-$394.0K	-$350.9K	-$386.7K
YoY Change	-1.06%	-9.28%	1130.45%
Income Tax	$22.00K	$24.00K
% Of Pretax Income
Net Earnings	-$416.0K	-$374.9K	-$386.7K
YoY Change	4.46%	-3.07%	1149.98%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.03
Diluted Earnings Per Share	-$0.16	-$0.13	-$51.83K
COMMON SHARES
Basic Shares Outstanding	2.410M shares	2.980M shares
Diluted Shares Outstanding		11.40M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$699.3K	$148.4K	$156.8K
YoY Change	299.45%	-5.34%	33.89%
Cash & Equivalents	$699.3K	$148.4K	$156.8K
Short-Term Investments
Other Short-Term Assets	$70.15K	$116.0K	$286.9K
YoY Change	-77.26%	-59.58%	30.9%
Inventory
Prepaid Expenses		$116.0K
Receivables
Other Receivables
Total Short-Term Assets	$769.5K	$264.4K	$443.7K
YoY Change	59.11%	-40.42%	31.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.286M	$13.65M	$57.38M
YoY Change	-87.48%	-76.21%
Other Assets
YoY Change
Total Long-Term Assets	$7.286M	$13.65M	$57.38M
YoY Change	-87.48%	-76.21%
TOTAL ASSETS
Total Short-Term Assets	$769.5K	$264.4K	$443.7K
Total Long-Term Assets	$7.286M	$13.65M	$57.38M
Total Assets	$8.055M	$13.92M	$57.83M
YoY Change	-86.27%	-75.94%	17096.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$936.5K	$432.7K	$1.717M
YoY Change	334.48%	-74.8%	4348.8%
Accrued Expenses	$2.350M	$2.576M
YoY Change	24.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.287M	$3.008M	$1.717M
YoY Change	56.07%	75.22%	400.96%
LONG-TERM LIABILITIES
Long-Term Debt	$3.603M	$3.234M	$0.00
YoY Change	528.37%
Other Long-Term Liabilities	$1.535M	$1.510M	$2.362M
YoY Change	-41.61%	-36.05%
Total Long-Term Liabilities	$5.138M	$4.745M	$2.362M
YoY Change	60.43%	100.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.287M	$3.008M	$1.717M
Total Long-Term Liabilities	$5.138M	$4.745M	$2.362M
Total Liabilities	$8.425M	$7.753M	$4.079M
YoY Change	58.7%	90.08%	1090.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.621M	-$7.288M	-$2.919M
YoY Change	110.86%	149.69%
Common Stock	$173.00	$173.00	$173.00
YoY Change	0.0%	0.0%	20.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.621M	-$7.288M	-$869.2K
YoY Change
Total Liabilities & Shareholders Equity	$8.055M	$13.92M	$57.83M
YoY Change	-86.27%	-75.94%	17096.79%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$416.0K	-$374.9K	-$386.7K
YoY Change	4.46%	-3.07%	1149.98%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$127.4K	-$26.57K	-$348.2K
YoY Change	-54.77%	-92.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$6.365M	-$416.9K
YoY Change	-1210.05%
Cash From Investing Activities	$6.365M	-$416.9K
YoY Change	-1210.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.687M	312.5K	500.0K
YoY Change	-751.09%	-37.5%
NET CHANGE
Cash From Operating Activities	-127.4K	-26.57K	-348.2K
Cash From Investing Activities	6.365M	-416.9K
Cash From Financing Activities	-5.687M	312.5K	500.0K
Net Change In Cash	550.9K	-130.9K	151.8K
YoY Change	2907.21%	-186.29%
FREE CASH FLOW
Cash From Operating Activities	-$127.4K	-$26.57K	-$348.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000000	shares
	dei	Entity File Number EntityFileNumber	001-40723
	dei	Entity Registrant Name EntityRegistrantName	ABRI SPAC I, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2861807
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9663 Santa Monica Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 1091
	dei	Entity Address City Or Town EntityAddressCityOrTown	Beverly Hills
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90210
	dei	City Area Code CityAreaCode	(424)
	dei	Local Phone Number LocalPhoneNumber	732-1021
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2410226	shares
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148389	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	381293	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	115967	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	252463	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	264356	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	633756	usd
CY2023Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	13650778	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	12841399	usd
CY2023Q2	us-gaap	Assets Assets	13915134	usd
CY2022Q4	us-gaap	Assets Assets	13475155	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	432649	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	441739	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2575551	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2113078	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3008200	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2554817	usd
CY2023Q2	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	1584284	usd
CY2022Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	1146784	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1650000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1250000	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10311	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	17676	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1500000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1500000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	7752795	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6469277	usd
CY2023Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1252372	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1252372	shares
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-109002	usd
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	13450571	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	12841399	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1728078	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1728078	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1728078	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1728078	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	173	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	173	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7288405	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5835694	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7288232	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5835521	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13915134	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13475155	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	341146	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	307154	usd
	us-gaap	Professional Fees ProfessionalFees	761279	usd
	us-gaap	Professional Fees ProfessionalFees	1401354	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	186903	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	197451	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	344626	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	498960	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	528049	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	504605	usd
	us-gaap	Operating Expenses OperatingExpenses	1105905	usd
	us-gaap	Operating Expenses OperatingExpenses	1900314	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-528049	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-504605	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1105905	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1900314	usd
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	160991	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	76629	usd
	us-gaap	Interest Income Other InterestIncomeOther	303001	usd
	us-gaap	Interest Income Other InterestIncomeOther	81973	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16203	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-41244	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7365	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	177194	usd
CY2022Q2	us-gaap	Interest Income Operating InterestIncomeOperating	117873	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	310366	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	190975	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-350855	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-386732	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-795539	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1709339	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-374855	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-386732	usd
	us-gaap	Net Income Loss NetIncomeLoss	-843539	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1709339	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5835521	usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-307596	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-468684	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6611801	usd
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-301576	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-374855	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7288232	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3135052	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-1099501	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1322607	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	712944	usd
CY2022Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-1195374	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-386732	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-869162	usd
	us-gaap	Net Income Loss NetIncomeLoss	-843539	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1709339	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7365	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-109002	usd
	us-gaap	Interest And Dividend Income Securities Held To Maturity InterestAndDividendIncomeSecuritiesHeldToMaturity	81973	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-136496	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-72868	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	453383	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1029259	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-261025	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-798187	usd
	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	809379	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-809379	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	400000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	437500	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	800000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	837500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	800000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-232904	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1813	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	381293	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154942	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148389	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156755	usd
	us-gaap	Stock Issued1 StockIssued1	609172	usd
	us-gaap	Stock Issued1 StockIssued1	2294875	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 — NATURE OF THE ORGANIZATION AND BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abri SPAC I, Inc (“Abri” or the “Company”) was incorporated in the State of Delaware on March 18, 2021. The Company’s business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (our “Initial Business Combination”). Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Abri SPAC I, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, and the date of this filing, the Company had not commenced core operations. <span>All activity for the period from March 18, 2021 (inception) through June 30, 2023 related to organizational activities, those necessary to consummate the initial public offering (“IPO”) and identify a target company for a business combination</span>. The Company will not generate any operating revenues until after the completion of the Initial Business Combination, at the <span>earliest. The Company generates non-operating income in the form of interest income and gains from the marketable securities held in the Trust Account, and gains or losses from the change in fair value of the warrant liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration statement pursuant to which the Company registered its securities offered in the IPO was declared effective on August 9, 2021. On August 12, 2021, the Company consummated its IPO of 5,000,000 units (each, a “Unit” and collectively, the “Units”), at $10.00 per Unit, generating gross proceeds of $50,000,000 and incurring offering costs of $973,988. The Company granted the underwriter a 45-day option to purchase up to an additional 750,000 Units at the IPO price to cover over-allotments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Simultaneously with the consummation of the closing of the Initial Public Offering, the Company completed the private sale of 276,250 units (the “Private Units”) to Abri Ventures I, LLC (“Abri Ventures”), the Company’s sponsor (the “Sponsor”) at a purchase price of $10.00 per Private Unit, generating gross proceeds to the Company of $2,762,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the IPO on August 12, 2021, an amount of $50,000,000 net proceeds from the IPO and sale of the Private Units was placed in a trust account in the United States maintained by Continental Stock Transfer & Trust Company, as trustee (the “Trust Account”). The funds held in the Trust Account were invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations so that we are not deemed to be an investment company under the Investment Company Act. Except with respect to interest earned on the funds held in the Trust Account, the Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of the Initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 12 months from the closing of the IPO (or up to 18 months from the closing of this offering with the mandatory extensions of the period of time to consummate an Initial Business Combination) or (B) with respect to any other provision relating to stockholders’ rights or pre-Initial Business Combination activity; or (iii) absent an Initial Business Combination within 12 months from the closing of the IPO (or up to 18 months from the closing of this offering with the mandatory extensions of the period of time to consummate an Initial Business Combination), the return of the funds held in the Trust Account to the public stockholders as part of redemption of the public shares. The Company’s amended and restated certificate of incorporation has been further amended by stockholders to extend the time in which the Company has to complete an Initial Business Combination to February 12, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2021, the underwriters notified the Company of their intent to exercise of the over-allotment option in part and, on August 23, 2021, the underwriters purchased 733,920 additional Units (the “Additional Units”) at $10.00 per Additional Unit upon the closing of the over-allotment option, generating additional gross proceeds of $7,339,200. On August 23, 2021, simultaneously with the sale of the Additional Units, the Company consummated the sale of an additional 18,348 Private Units at $10.00 per additional Private Unit (the “Additional Private Units”), generating additional gross proceeds of $183,480. A total of $7,339,200 of the net proceeds from the sale of the Additional Units and the Additional Private Units was deposited in the Trust Account, bringing the aggregate proceeds held in the Trust Account on that date to $57,339,200. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock exchange listing rules provide that the Initial Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the value of the assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable) at the time of the Company signing a definitive agreement in connection with the Initial Business Combination. The Company will only complete an Initial Business Combination if the post-Initial Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect an Initial Business Combination. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The payment to the Company’s Sponsor of a monthly fee of $10,000 is for general and administrative services including office space, utilities and secretarial support, which the Company records as operating expense on its statements of operations. However, pursuant to the terms of such agreement, the Company may delay payment of such monthly fee upon a determination by the audit committee that the Company lacks sufficient funds held outside the trust to pay actual or anticipated expenses in connection with the Initial Business Combination. Any such unpaid amount will accrue without interest and be due and payable no later than the date of the consummation of the Initial Business Combination. This arrangement is being agreed to by its Sponsor for the Company’s benefit. Management believes that the fee charged by the Sponsor is at least as favorable as what could have been obtained from an unaffiliated person. This arrangement will terminate upon completion of the Initial Business Combination or the distribution of the Trust Account to the public stockholders. Other than the $10,000 per month fee, no compensation of any kind (including finder’s fees, consulting fees or other similar compensation) will be paid to insiders, members of the management team or any of their respective affiliates, for services rendered prior to or in connection with the consummation of the Initial Business Combination (regardless of the type of transaction that it is). However, such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on the Company’s behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business combinations, as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine their operations. Since the role of present management after the Initial Business Combination is uncertain, the Company has no ability to determine what remuneration, if any, will be paid to those persons after the Initial Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The funds outside of the Trust Account are for working capital requirements in searching for an Initial Business Combination. The allocation such funds represents the Company’s best estimate of the intended uses of these funds. If the estimate of the costs of undertaking due diligence and negotiating our Initial Business Combination is less than the actual amount necessary to do so, the Company may be required to raise additional capital, the amount, availability and cost of which is currently unascertainable. In this event, the Company could seek such additional capital through loans or additional investments from insiders, members of management team or third parties, but the insiders, members of the Company’s management team or third parties are not under any obligation to advance funds to, or invest in the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will likely use substantially all of the net proceeds of this offering, including the funds held in the Trust Account, in connection with the Initial Business Combination and to pay expenses relating thereto, including the deferred underwriting commissions payable to the underwriter in an amount equal to 3.0% of the total gross proceeds raised in the offering upon consummation of the Initial Business Combination. To the extent that the Company’s capital stock is used in whole or in part as consideration to effect the Initial Business Combination, the proceeds held in the Trust Account which are not used to consummate an Initial Business Combination will be disbursed to the combined company and will, along with any other net proceeds not expended, be used as working capital to finance the operations of the target business. Such working capital funds could be used in a variety of ways, including continuing or expanding the target business’ operations, for strategic acquisitions and for marketing, research and development of existing or new products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent the Company is unable to consummate an Initial Business Combination, the Company will pay the costs of liquidation from the remaining assets outside of the Trust Account. If such funds are insufficient, the Company’s insiders have agreed to pay the funds necessary to complete such liquidation and have agreed not to seek repayment of such expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believes that it will not have sufficient available funds to operate for up to the next 12 months, assuming that the Initial Business Combination is not consummated during that time. However, if necessary, in order to meet the Company’s working capital needs following the consummation of this offering, the insiders may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the Initial Business Combination, without interest, or, at the lender’s discretion, up to $750,000 of the notes may be converted upon consummation of our Initial Business Combination into additional Private Warrants at a price of $1.00 per warrant. Notwithstanding, there is no guarantee that the Company will receive such funds. The Company’s stockholders have approved the issuance of the Private Warrants upon conversion of such notes, to the extent the holder wishes to so convert such notes at the time of the consummation of the Initial Business Combination. If the Company does not complete an Initial Business Combination, any loans and advances from the insiders or their affiliates, will be repaid only from amounts remaining outside the Trust Account, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their redemption rights with respect to their insider shares and any public shares they may hold in connection with the completion of the Initial Business Combination. In addition, the Sponsor and its officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their insider shares if the Company fails to complete an Initial Business Combination within the prescribed time frame. However, if its Sponsor or any of its officers, directors or affiliates acquire public shares in or after this offering, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if the Company fails to complete an Initial Business Combination within the prescribed time frame.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will provide its public stockholders with the opportunity to redeem all or a portion of their shares of common stock upon the completion of the Initial Business Combination either (i) in connection with a stockholder meeting called to approve the Initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed Initial Business Combination or conduct a tender offer will be made by the Company, solely in the Company’s discretion. The public stockholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the Initial Business Combination including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to the limitations. As of June 30, 2023, the amount in the Trust Account is approximately $10.90 per public share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock subject to redemption was classified as temporary equity upon the completion of the IPO and will subsequently be accreted to redemption value, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 480, <i>Distinguishing Liabilities from Equity</i>, (“ASC 480”). In such case, the Company will proceed with an Initial Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of an Initial Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Initial Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had 12 months from the closing of the IPO (the “Combination Period”) on August 9, 2021 to complete the Initial Business Combination. On August 5, 2022, pursuant to the Company’s certificate of incorporation and investment trust agreement, the Company deposited $573,392 into the Trust Account to extend the time to complete its Initial Business Combination for an additional three months, or until November 12, 2022. On November 1, 2022, in connection with a second extension, Abri deposited $573,392 (or $0.10 for each share of common stock issued in the IPO) into the Trust Account to extend the time to complete a business combination to February 12, 2023. The Company further amended the certificate of incorporation and investment trust agreement, as described below. If the Company is unable to complete its Initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the warrants, which will expire worthless if the Company fails to complete its Initial Business Combination prior to the mandatory liquidation date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Trust Account Redemptions</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 9, 2022, the Company held a special meeting of stockholders at which such stockholders voted to amend the Company’s amended and restated certificate of incorporation and its investment trust agreement, giving the Company the right to extend the date by which the Company must complete its Initial Business Combination up to six times for an additional one month each time, from February 12, 2023 to August 12, 2023, by depositing $87,500 into the Trust Account for each one-month extension. In connection with the special meeting, 4,481,548 shares of common stock were tendered for redemption, resulting in redemption payments of $45,952,278 out of the Trust Account. On February 6, 2023, March 10, 2023, April 11, 2023, May 11, 2023, June 9, 2023 and July 10, 2023, Abri deposited $87,500 into the Trust Account for each one-month extension (or a total of $525,000) to extend the time to complete a business combination to August 12, 2023, of which $437,500 had been deposited as of June 30, 2023. On August <span style="-sec-ix-hidden: hidden-fact-52"><span style="-sec-ix-hidden: hidden-fact-53"><span style="-sec-ix-hidden: hidden-fact-54"><span style="-sec-ix-hidden: hidden-fact-55"><span style="-sec-ix-hidden: hidden-fact-56">7, 2023</span></span></span></span></span>, the Company held a second special meeting of stockholders at which such stockholders voted to amend the Company’s amended and restated certificate of incorporation and its investment trust agreement, giving the Company the right to extend the date by which the Company must complete its Initial Business Combination from August 12, 2023 to February 12, 2024 with no additional payment to the Company’s trust account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks and Uncertainties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management continues to evaluate the impact of the Russia-Ukraine war on the economy and the capital markets and has concluded that, while it is reasonably possible that such events could have negative effects on the Company’s financial position, results of its operations, and/or search for a target company, the specific impacts are not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Going Concern and Management Liquidity Plans</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, the Company had cash of $148,389 and working capital deficiency of $2,743,844. The Company’s liquidity needs through the date of this filing have been satisfied through proceeds from notes payable and advances from a related party and from the issuance of common stock. The liquidity needs consist of paying existing accounts payable, identifying and evaluating prospective business combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating an Initial Business Combination. Although certain of the Company’s initial stockholders, officers and directors or their affiliates have committed to loan the Company funds from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, there is no guarantee that the Company will continue to receive such funds.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, the accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of financing and acquisition plans. Management plans to address this uncertainty during the period leading up to the Initial Business Combination. The Company cannot provide any assurance that its plans to raise capital or to consummate an Initial Business Combination will be successful. Based on the foregoing, management believes that the Company will not have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of the Initial Business Combination or one year from this filing. These factors raise substantial doubt about the Company’s ability to continue as a going concern.</p>
	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	276250	shares
	aspa	Purchase Price Per Unit PurchasePricePerUnit	10
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2762500	usd
CY2021Q3	aspa	Additional Private Sale Units AdditionalPrivateSaleUnits	18348	shares
CY2021Q3	aspa	Additional Private Per Share AdditionalPrivatePerShare	10
CY2021Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	183480	usd
CY2021Q3	us-gaap	Demutualization By Insurance Entity Securities Issued Amount Of Net Proceeds DemutualizationByInsuranceEntitySecuritiesIssuedAmountOfNetProceeds	7339200	usd
CY2021Q3	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	57339200	usd
	aspa	Percentage Of Fair Market Value PercentageOfFairMarketValue	0.80	pure
	aspa	Percentage Of Outstanding Voting Rights PercentageOfOutstandingVotingRights	0.50	pure
	aspa	General And Administrative Services GeneralAndAdministrativeServices	10000	usd
	aspa	Trust Account Public Stockholders TrustAccountPublicStockholders	10000	usd
	aspa	Total Gross Proceeds Raised Percentage TotalGrossProceedsRaisedPercentage	0.03	pure
	aspa	Public Per Share PublicPerShare	10.9
CY2023Q2	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	5000001	usd
CY2022Q3	us-gaap	Deposits Deposits	573392	usd
CY2023Q1	us-gaap	Deposits Deposits	87500	usd
CY2023Q1	us-gaap	Deposits Deposits	87500	usd
CY2023Q2	us-gaap	Deposits Deposits	87500	usd
CY2023Q2	us-gaap	Deposits Deposits	87500	usd
CY2023Q2	us-gaap	Deposits Deposits	87500	usd
CY2023Q3	us-gaap	Deposits Deposits	87500	usd
CY2023Q2	us-gaap	Deposits Deposits	525000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	148389	usd
CY2023Q2	aspa	Working Capital WorkingCapital	2743844	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	aspa	Maturity Terms MaturityTerms	P180D
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	165000	shares
CY2023Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	165000	usd
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	80000	shares
CY2022Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	80000	usd
CY2023Q2	us-gaap	Collateralized Agreements CollateralizedAgreements	70000	usd
	aspa	Companys Accretion Approximately Recorded CompanysAccretionApproximatelyRecorded	609172	usd
	us-gaap	Accretion Expense AccretionExpense	200206	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage. As of June 30, 2023 and December 31, 2022, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Derivative Financial Instruments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815, <i>Derivatives and Hedging</i>. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the issuance date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-374855	usd
CY2023Q2	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-301576	usd
CY2023Q2	aspa	Temporary Equity Accretion To Redemption Value1 TemporaryEquityAccretionToRedemptionValue1	-676431	usd
CY2022Q2	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-386732	usd
CY2022Q2	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-1195374	usd
CY2022Q2	aspa	Temporary Equity Accretion To Redemption Value1 TemporaryEquityAccretionToRedemptionValue1	-1582106	usd
	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-843539	usd
	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-609172	usd
	aspa	Temporary Equity Accretion To Redemption Value1 TemporaryEquityAccretionToRedemptionValue1	-1452711	usd
	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-1709339	usd
	aspa	Accretion Of Temporary Equity To Redemption Value AccretionOfTemporaryEquityToRedemptionValue	-2294875	usd
	aspa	Temporary Equity Accretion To Redemption Value1 TemporaryEquityAccretionToRedemptionValue1	-4004214	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	573392	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	573392	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	87500	usd
	aspa	Outstanding Aggregate Amount OutstandingAggregateAmount	1584284	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1250000	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	300000	usd
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	10
	aspa	Outstanding Under Note OutstandingUnderNote	1250000	usd
CY2022	aspa	Outstanding Under Note OutstandingUnderNote	1250000	usd
	us-gaap	Other General Expense OtherGeneralExpense	10000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	30000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	60000	usd
CY2022Q4	us-gaap	Collateralized Agreements CollateralizedAgreements	10000	usd
	aspa	Total Consideration TotalConsideration	114000000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2000000	shares
	aspa	Founder Shares Percentage FounderSharesPercentage	0.50	pure
	aspa	Common Stock Equals Or Exceeds Per Shares CommonStockEqualsOrExceedsPerShares	12.5
	aspa	Business Combination Remaining Percentage BusinessCombinationRemainingPercentage	0.50	pure
	aspa	Underwriters Underwriters	100	usd
	aspa	Option To Purchase Share OptionToPurchaseShare	300000	shares
CY2023Q2	aspa	Sale Of Stocks Price Per Shares SaleOfStocksPricePerShares	11.5
	aspa	Expired Term ExpiredTerm	P5Y
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	300000	shares
	aspa	Common Stock Shares CommonStockShares	300000	shares
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	300000	shares
	aspa	Registration Rights RegistrationRights	Notwithstanding the foregoing, the underwriters and their related persons may not (i) have more than one demand registration right at our expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration statement, and (iii) exercise their “piggy-back” registration rights more than seven (7) years from the effective date of the registration statement.
CY2021Q3	aspa	Cash Payment CashPayment	100	usd
	aspa	Proceeds From Issuance Of Share ProceedsFromIssuanceOfShare	100000000	shares
CY2023Q2	aspa	Common Stocks Par Or Stated Value Per Share CommonStocksParOrStatedValuePerShare	0.0001
CY2023Q2	aspa	Preferred Stock Share Authorized PreferredStockShareAuthorized	1000000	shares
CY2023Q2	aspa	Preferred Stocks Par Or Stated Value Per Share PreferredStocksParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	11.5
	aspa	Initial Business Combination InitialBusinessCombination	P1Y
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
	aspa	Description Of Warrants For Redemption DescriptionOfWarrantsForRedemption	We may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant: ●at any time while the warrants are exercisable; ●upon a minimum of 30 days’ prior written notice of redemption; ●if, and only if, the last sales price of our shares of common stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption; and ●if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.
	aspa	Trigger Price TriggerPrice	16.5
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	11.5
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2021Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	52323289	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	6470389	usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-45952279	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	12841399	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	609172	usd
CY2023Q2	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	13450571	usd
	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	276250	shares
	aspa	Purchase Price Per Unit PurchasePricePerUnit	10
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2762500	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	aspa	Underwriters Underwriters	100	usd
	aspa	Option To Purchase Share OptionToPurchaseShare	300000	shares
	aspa	Warrants Expire WarrantsExpire	P5Y
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	300000	shares
	aspa	Common Stock Shares CommonStockShares	300000	shares
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	300000	shares
CY2021Q3	aspa	Cash Payment CashPayment	100	usd
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	18348	shares
CY2021Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	183480	usd
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	aspa	Fair Value Of Public Warrants Per Share fairValueOfPublicWarrantsPerShare	0.6
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	10311	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y3M
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7365	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	61865	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y9M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.025	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0301	pure
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-41244	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-109002	usd
CY2023Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	13650778	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	10311	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	12841399	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	17676	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.07	pure
CY2022Q2	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.06	pure
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q3	aspa	Minimum Tax MinimumTax	0.15	pure
CY2022Q3	aspa	Excessof Cost ExcessofCost	1000000000	usd
CY2022Q3	aspa	Excise Tax ExciseTax	0.01	pure
	us-gaap	Interest And Dividend Income Securities Held To Maturity InterestAndDividendIncomeSecuritiesHeldToMaturity		usd
	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001854583

Files In Submission

Name	View Source	Status
aspa-20230630_pre.xml	Edgar Link	unprocessable
0001213900-23-067177-index-headers.html	Edgar Link	pending
0001213900-23-067177-index.html	Edgar Link	pending
0001213900-23-067177.txt	Edgar Link	pending
0001213900-23-067177-xbrl.zip	Edgar Link	pending
aspa-20230630.xsd	Edgar Link	pending
aspa-20230630_cal.xml	Edgar Link	unprocessable
f10q0623ex31-1_abrispac1.htm	Edgar Link	pending
f10q0623ex31-2_abrispac1.htm	Edgar Link	pending
f10q0623ex32_abrispac1.htm	Edgar Link	pending
f10q0623_abrispac1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aspa-20230630_def.xml	Edgar Link	unprocessable
aspa-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_abrispac1_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAUD
Collective Audience, Inc. Stock $caud

2023 Q3 Form 10-Q Financial Statement

#000121390023067177 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAUD Collective Audience, Inc. Stock $caud

2023 Q3 Form 10-Q Financial Statement

#000121390023067177 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAUD
Collective Audience, Inc. Stock $caud